Max Planck Institute for Molecular Genetics developed the ModCell system and licensed it to Alacris.
GSK will provide pre-clinical biology data from oncology research to Alacris, which will apply the system for drug stratification.
The in silico effect of the inhibitor will be determined, by Alacris’ Systems Biology model, in its virtual clinical trial system.
Cancer cell lines and high probability cancers that respond to the inhibitor can be determined based on whole genome and transcriptome data integrated in the Alacris’ cancer model ModCell.